{"product_id":"icu-marketing-mix","title":"(ICU) SeaStar Medical Holding Corporation Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis SeaStar Medical Holding Corporation 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format. The page shows a genuine preview\/sample of the analysis so you can evaluate style and content; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQUELIMMUNE HDE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQUELIMMUNE HDE is SeaStar Medical Holding Corporation’s lead commercial product and first FDA-authorized marketed therapy, aimed at pediatric acute kidney injury with sepsis that needs continuous renal replacement therapy. In the 4P mix, this is the core Product because it targets a high-risk hospital use case with a narrow, specialist-driven label. Its HDE status matters, since Humanitarian Device Exemption products are cleared for rare conditions and help shape pricing, access, and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelective Cytopheretic Device platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s Selective Cytopheretic Device platform is an extracorporeal immune-modulation system that binds and regulates activated effector cells in the blood circuit. Its aim is to calm hyperinflammation and blunt cytokine storm, a pathway tied to acute organ injury and high-care ICU use. The product’s value sits in turning a drug-free blood-treatment platform into a targeted inflammatory control tool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlood-contacting therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation's blood-contacting therapy is a hospital-only device used with dialysis-type critical care support, so each use is tied to an ICU or inpatient procedure, not a retail sale. Because it works outside the body through the extracorporeal circuit, it fits the market as a procedure-linked product with trained staff and repeated device use. The U.S. dialysis population is over 550,000, which shows the scale of the care setting this product serves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdult AKI pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation is advancing its adult AKI pipeline for critically ill patients on CRRT, expanding the platform beyond pediatrics. This target is attractive because severe AKI is common in ICUs, and CRRT is often used when kidney failure is life-threatening. The adult program could widen the addressable market well beyond the pediatric niche. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdult ICU patients on CRRT\u003c\/li\u003e\n\u003cli\u003eExpansion beyond pediatrics\u003c\/li\u003e\n\u003cli\u003eHigher market reach potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroad critical care pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation broad critical care pipeline extends its inflammation-control approach into cardiorenal syndrome in congestive heart failure, including patients with and without LVADs, plus myocardial stunning in end-stage renal disease and hepatorenal syndrome. Acute kidney injury can affect up to 50% of ICU patients, so even small gains can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets multiple ICU syndromes\u003c\/li\u003e\n\u003cli\u003eUses one inflammation-control concept\u003c\/li\u003e\n\u003cli\u003eFits high-need, high-risk care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeaStar’s QUELIMMUNE Targets a High-Need ICU Kidney Crisis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s Product is QUELIMMUNE HDE, a first FDA-authorized, hospital-only immune-modulation device for pediatric sepsis-associated acute kidney injury on CRRT. Its Humanitarian Device Exemption fits a rare, high-acuity use case and supports specialist adoption.\u003c\/p\u003e\n\u003cp\u003eThe platform also aims at adult AKI and other ICU syndromes, widening use beyond pediatrics. With acute kidney injury affecting up to 50% of ICU patients, the addressable need is large.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eNeed\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eQUELIMMUNE HDE\u003c\/td\u003e\n\u003ctd\u003ePediatric AKI on CRRT\u003c\/td\u003e\n\u003ctd\u003eFDA-authorized\u003c\/td\u003e\n\u003ctd\u003eHigh-acuity ICU\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific breakdown of SeaStar Medical Holding Corporation’s 4P marketing mix, grounded in real market positioning and strategic context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClarifies SeaStar Medical’s 4Ps to quickly ease strategic confusion and support faster marketing decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary industry reports, regulatory filings, and benchmark datasets to speed due diligence and verify SeaStar Medical market, pricing, and unit-economics claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDenver, Colorado headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation is headquartered in Denver, Colorado, where corporate, regulatory, and commercialization work is managed from one U.S. base. The Denver site helps coordinate distribution and partner activity across 3 core functions: governance, compliance, and market rollout. That central setup supports faster execution in the U.S. medtech market, where regulated launch timing can shape revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. hospital market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation targets the U.S. hospital market because QUELIMMUNE is used in ICU and other institutional critical care settings, not retail channels. The U.S. has about 6,100 hospitals and roughly 920,000 staffed beds, so distribution depends on hospital procurement, clinical adoption, and direct deployment inside care teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric ICU access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePediatric ICU access is narrow and clinical: SeaStar Medical Holding Corporation’s lead use is for pediatric acute kidney injury in critically ill children, so adoption starts in pediatric intensive care units that already run CRRT programs. AKI affects about 30% to 50% of critically ill children, but only a limited set of hospitals have the staff and machines to deliver renal replacement therapy. That makes site selection and CRRT footprint the key gate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCRRT-capable centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s therapy is placed in CRRT-capable centers because it must run through continuous renal replacement therapy in the ICU. That puts the buyer set in nephrology and critical care units that already have dialysis machines, trained staff, and extracorporeal blood-flow protocols.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eICU CRRT sites are the key channel\u003c\/li\u003e\n\u003cli\u003eDialysis-ready units are the target\u003c\/li\u003e\n\u003cli\u003ePlacement follows existing workflows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic and referral hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic and referral hospitals are SeaStar Medical Holding Corporation's core place channel, because the sickest ICU patients are concentrated in tertiary and quaternary centers and are most likely to get a novel device evaluation. In 2025, this means specialist-led adoption, not broad outpatient reach, which fits a high-acuity model with long clinical review cycles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBest fit: tertiary and quaternary ICUs\u003c\/li\u003e\n\u003cli\u003eTargets the sickest, highest-need patients\u003c\/li\u003e\n\u003cli\u003eSupports specialist-driven device use\u003c\/li\u003e\n\u003cli\u003eLimits need for wide outpatient distribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S.-Centered Hospital Strategy Drives QUELIMMUNE Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s place strategy is U.S.-centered, with Denver used to manage regulation, partners, and launch work. QUELIMMUNE is placed in ICU and CRRT-capable hospitals, so adoption depends on nephrology and critical care teams, not retail channels. The core market is tertiary and quaternary children’s hospitals, where severe AKI cases concentrate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eDenver, Colorado\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hospitals\u003c\/td\u003e\n\u003ctd\u003eAbout 6,100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaffed beds\u003c\/td\u003e\n\u003ctd\u003eAbout 920,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eICU CRRT sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eSeaStar Medical Holding Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual SeaStar Medical Holding Corporation 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the full, ready-to-use document covering Product, Price, Place, and Promotion with actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA HDE milestone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA Humanitarian Device Exemption is a strong promo asset for SeaStar Medical Holding Corporation because it gives QUELIMMUNE a formal regulatory stamp in a rare-use setting. The HDE route is limited to diseases affecting fewer than 8,000 U.S. patients a year, so it signals clinical need and helps hospitals trust the product in acute kidney injury linked to sepsis. That FDA status also sets QUELIMMUNE apart in a narrow pediatric market for patients weighing 10 to less than 50 kg.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data dissemination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s promotion leans on clinical data, not broad ads, because physicians and hospitals buy on proof. The company uses study results, safety data, and peer-reviewed or conference-presented findings to show how its device performs in real care. That fits a market where the first FDA-authorized QUELIMMUNE therapy for pediatric acute kidney injury came in 2024, so evidence drives adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congress presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation uses medical congress presence in nephrology, critical care, and pediatrics to reach the specialists who manage CRRT and AKI, where more than 2 million AKI hospital cases occur each year in the U.S. alone. These forums support physician education, build clinical trust, and create direct lead flow for adoption discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKey opinion leader outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s audience is clinician-led, so key opinion leader outreach is central: it helps doctors explain the device’s mechanism and patient-selection criteria in ICU settings, where the therapy is novel and high-stakes. In 2025, the company still needed trusted clinical voices to support adoption of QUELIMMUNE after its FDA Humanitarian Device Exemption, because bedside use depends on clear case selection and workflow fit. That makes KOL education a direct driver of awareness, confidence, and trial use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eClinician trust drives ICU adoption.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eKOLs clarify mechanism and selection.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNovel therapies need bedside proof.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor and corporate communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation uses press releases, SEC filings, and earnings materials to promote its investor and corporate story. These updates track QUELIMMUNE commercialization, milestones, and pipeline steps, helping both healthcare buyers and investors follow progress after its 2023 FDA De Novo authorization for the first marketed product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTracks commercialization progress\u003c\/li\u003e\n\u003cli\u003eShares SEC and earnings updates\u003c\/li\u003e\n\u003cli\u003eSupports investor and clinician awareness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeaStar Builds ICU Trust with KOLs, Congresses, and FDA Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s promotion is specialist-led and proof-based: QUELIMMUNE’s FDA Humanitarian Device Exemption and 2024 first authorization help build trust with ICU and nephrology buyers. The company leans on congresses, KOLs, and clinical data to reach the more than 2 million U.S. AKI hospital cases each year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOLs\u003c\/td\u003e\n\u003ctd\u003eClinical trust\u003c\/td\u003e\n\u003ctd\u003eICU adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCongresses\u003c\/td\u003e\n\u003ctd\u003ePhysician education\u003c\/td\u003e\n\u003ctd\u003eAKI and CRRT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA HDE\u003c\/td\u003e\n\u003ctd\u003eRegulatory proof\u003c\/td\u003e\n\u003ctd\u003eRare use under 8,000 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo public list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation has not published a standard list price for QUELIMMUNE, which fits a hospital-only device sold through negotiated contracts, not shelf pricing. The company’s model is aimed at inpatient use in critically ill pediatric patients, so pricing is usually set case by case with hospitals and payers rather than posted publicly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation sells into hospitals and health systems, so pricing is usually negotiated by account or facility, not set at a single list price. In this model, each order depends on clinical use, formulary approval, and procurement sign-off, which can lengthen sales cycles but support stickier contracts. For a device sold into acute care, that means access and reimbursement decisions matter as much as the product itself.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcedure-linked economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s QUELIMMUNE is used in a CRRT setting, so the price is tied to a hospital procedure episode and folded into the ICU budget, not sold as a consumer cash price. That means buying is judged against the full critical-care case, where one ICU day can cost thousands of dollars and CRRT is billed as part of the stay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement-dependent adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s pricing has to fit hospital reimbursement, not just device value. In critical care, a product can stall if the hospital cannot code and bill it cleanly, even when clinical need is clear. CMS’s 2025 inpatient hospital payment update was 2.9%, so any new device must protect already thin margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement drives ICU adoption.\u003c\/li\u003e\n\u003cli\u003eBilling codes shape hospital margins.\u003c\/li\u003e\n\u003cli\u003ePrice must fit payment pathways.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSingle-patient therapy model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation uses a single-patient therapy model, so pricing fits per-treatment or per-patient economics, not a subscription. That matches acute ICU use, where one severe episode can cost tens of thousands of dollars per stay, and the U.S. ICU market still centers on episodic care. For buyers, the value case is tied to reducing high-cost, high-risk ICU events. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePer-patient pricing fits acute care\u003c\/li\u003e\n\u003cli\u003eBest for severe ICU episodes\u003c\/li\u003e\n\u003cli\u003eValue depends on avoided ICU costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeaStar’s ICU Pricing Hinges on Hospital Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeaStar Medical Holding Corporation’s price is negotiated hospital by hospital, not posted as a list price, because QUELIMMUNE is sold for ICU and CRRT use. That makes reimbursement and coding central to adoption; CMS’s 2025 inpatient update was 2.9%, so pricing must fit thin hospital margins and per-patient economics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePricing model\u003c\/td\u003e\n\u003ctd\u003eNegotiated, not public\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse setting\u003c\/td\u003e\n\u003ctd\u003eHospital ICU \/ CRRT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement pressure\u003c\/td\u003e\n\u003ctd\u003eCMS 2025 IPPS +2.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234536956169,"sku":"icu-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/icu-marketing-mix.webp?v=1785721596","url":"https:\/\/dcfanalyst.com\/products\/icu-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}